By the Children's Health Defense Team

Since the emergence of HIV in the early 1980s, Dr. Anthony Fauci has acquired decades of experience being the front man for a network of powerful Big Pharma and Big Medicine interests. This network (one of the most conspicuous members of which is Fauci's friend and patron Bill Gates) profits handsomely from regularly declared epidemics and pandemics via the unending flow of cash that such events inevitably direct to pharmaceutical interventions—and especially vaccination.

Fauci's father was a pharmacist, and Fauci himself has specialized in the pharmacological "regulation" of the human immune system. He hitched his professional wagon to vaccines early on, and his agency's single-minded focus on vaccine "solutions"—and simultaneous denial of serious vaccine-created problems such as vaccine failure and pathogenic priming—has long threatened to suffocate other avenues of exploration, whether for prevention or treatment.

Although Fauci has never been able to deliver on the promise of an HIV vaccine made when he took the helm of NIAID (the National Institute of Allergy and Infectious Diseases) in 1984, he has been highly successful—for decades—in attracting billions for HIV vaccine research. And as new threats like Ebola and Zika have emerged, the groundwork laid during the HIV era has allowed vaccines to continue to monopolize both attention and funding.

Fauci is not only a productive agency fundraiser but also a prolific publisher. The National Library of Medicine search engine (PubMed) pulls up nearly 300 publications that he has authored or co-authored over the last two decades. And many of these—like Fauci's 2017 remarks at Georgetown University that the Trump administration should expect a "surprise outbreak" within "the next few years"—not only foreshadow future events but also provide major hints of his network's vaccine bias.

In 2003, for example, Fauci and coauthors (including then-CDC-director Julie Gerberding) spelled out a vision in Science for a "global vaccine enterprise." Although their focus back then was on HIV, the proposed measures sound eerily similar to what many of these same players have called for in conjunction with COVID-19 vaccines—including "quickly measuring the effectiveness of vaccine protection as prototype vaccine candidates are identified," expanding manufacturing resources "to speed [vaccine candidates'] use in human trials" and "systematically explor[ing] . . . delivery systems for vaccines." It should probably come as no surprise, then, to discover similar fortune-telling tendencies in some of Fauci's other publications.